News about Clinical Trials

Neurosterix Completes Phase 1 Studies of NTX-253 for Schizophrenia

Neurosterix has completed Phase 1 studies of NTX-253 and plans to begin Phase 2 development; Addex retains a 20 percent equity interest in the company.

Clinical Trials | 09/10/2026 | By News Bureau

argenx Updates Phase 3 UNITY Trial of Efgartigimod

argenx plans to stop its phase 3 UNITY study of efgartigimod SC in Sjögren’s disease following an IDMC recommendation based on interim analysis.

Clinical Trials | 09/10/2026 | By News Bureau

Transcripta Bio and Synfini Target Huntington's Disease Driver

Transcripta Bio and Synfini use AI-driven chemistry and transcriptome-scale biology to identify a validated Huntington’s disease lead candidate in weeks.

Clinical Trials | 09/10/2026 | By News Bureau

ArriVent's FURVENT Phase 3 Trial Misses Primary PFS Endpoint

ArriVent’s FURVENT Phase 3 trial of firmonertinib in EGFR exon 20 insertion-mutant NSCLC did not meet its primary PFS endpoint.

Clinical Trials | 07/10/2026 | By News Bureau

Lundbeck to Present Movement Disorder Data at MDS 2026

Lundbeck presents new movement disorder research covering MSA clinical development and advanced Parkinson’s disease.

Clinical Trials | 05/10/2026 | By News Bureau

Litfulo Shows Significant Repigmentation Benefits in Phase 3

Pfizer’s two phase 3 trials showed significant improvements in facial and total body repigmentation compared with placebo.

Clinical Trials | 05/10/2026 | By News Bureau

Teva Reports Ecopipam Data in Pediatric Tourette Syndrome

Teva Pharmaceuticals has reported new ecopipam data showing clinically meaningful tic reduction in about 70 percent of pediatric Tourette Syndrome patients within 8 weeks.

Clinical Trials | 05/10/2026 | By News Bureau

Sun Pharma Presents Long-Term Leqselvi Data

Sun Pharma presents long-term safety and efficacy data for Leqselvi in adults with severe alopecia areata at the EADV Congress 2026.

Clinical Trials | 03/10/2026 | By News Bureau

Roche Reports New Real-World Vabysmo Data Across Retinal Conditions

Roche’s VOYAGER study provides real-world data on Vabysmo’s effectiveness, durability and safety across multiple retinal conditions.

Clinical Trials | 03/10/2026 | By News Bureau

Pierre Fabre Resubmits Tabelecleucel BLA to FDA

Pierre Fabre Pharmaceuticals resubmits tabelecleucel BLA for treatment of Epstein-Barr virus positive -post-transplant lymphoproliferative disease to the FDA.

Clinical Trials | 03/10/2026 | By News Bureau